Survodutide could become first global glucagon/GLP-1 dual agonist, new phase III findings suggest.
Credit: ricochet64 / Shutterstock.com
New topline phase III data could position Boehringer Ingelheim’s glucagon/GLP-1 dual agonist survodutide as the first global glucagon/GLP-1 dual agonist.
The Phase III SYNCHRONIZE-1 trial found that the treatment not only enabled significant weight loss but could potentially also support liver function.
Specifically, participants given survodutide experienced sustained weight loss of up to an average of 16.6 percent after 76 weeks versus 3.2 percent in the placebo arm.
The trial also enabled up to 85.1 percent of participants to reduce their body weight by ≥5 percent, versus 38.8 percent with placebo.
These latest results follow promising phase II, 48-week trial data on survodutide published in 2024. The company’s former Head of Human Pharma said at the time, that these “breakthrough [findings] further reinforce survodutide’s potential as a best-in-class treatment for people living with MASH”.
Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma, Boehringer Ingelheim, said that its latest topline data for their GLP-1 dual agonist “strengthen our confidence in survodutide as a treatment candidate capable of addressing obesity and potentially offering targeted weight loss to help address connected conditions including liver disease.
“Survodutide has the potential to be the first global glucagon/GLP-1 dual agonist to help the more than 1 billion people living with obesity and MASH”
“Survodutide has the potential to be the first global glucagon/GLP-1 dual agonist to help the more than 1 billion people living with obesity and MASH.”
Full data from the phase III trial will be presented at the American Diabetes Association’s (ADA) 2026 Scientific Sessions in June.
Earlier this year, Roche released promising phase II data for its injectable GLP-1/GIP receptor agonist. Like survodutide, CT-388 illustrated dual therapeutic benefit. However, Roche’s therapy demonstrated promise not only for achieving weight loss but in pre-diabetes too. At Week 48, 73 percent of these participants achieved normal blood glucose levels.
No comments yet